What type of study is this?

This is a Meta-Analysis study (also classified as: Systematic Review).

December 8, 2025BloodOpen Access

Preemptive Rituximab in patients with ADAMTS13 relapse in thrombotic thrombocytopenic purpura: A systematic review

View Full Paper

Ask AI

Bookmark

Authors

MMMuhammad Umair MushtaqHealth Innovations (United States)MJMichael Jaglal

Discussion

Member takes

Implication

Systematic review shows preemptive Rituximab reduces relapse rate in thrombotic thrombocytopenic purpura patients with low ADAMTS13 levels, implying effective treatment.

Key Points

Preemptive Rituximab significantly decreased the relapse rate in 137 patients with thrombotic thrombocytopenic purpura and low ADAMTS13.
The treatment resulted in a median cumulative incidence of 0 episodes per year, with follow-up over 35.8 months.
Systematic review of clinical trials revealed a notable safety profile, with adverse events reported in 21% of patients, all low grade.
Further research is necessary to confirm results and assess long-term outcomes with larger randomized trials.

Cite This Study

Mushtaq et al. (2025) studied this question.

synapsesocial.com/papers/69362f444fa91c937236d629 https://doi.org/10.1182/blood-2025-1333

View Full Paper

Ask AI

Bookmark

Implication

Systematic review shows preemptive Rituximab reduces relapse rate in thrombotic thrombocytopenic purpura patients with low ADAMTS13 levels, implying effective treatment.

Preemptive Rituximab in patients with ADAMTS13 relapse in thrombotic thrombocytopenic purpura: A systematic review

Discussion

Member takes

Implication

Key Points

Cite This Study

Preemptive Rituximab in patients with ADAMTS13 relapse in thrombotic thrombocytopenic purpura: A systematic review

Discussion

Member takes

Implication

Key Points

Cite This Study

Also Consider

Also Consider